Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II

J. A. Campain, R. Padmanabhan, J. Hwang, M. M. Gottesman, I. Pastan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. To characterize resistance to this drug, the human melanoma cell line, FEM-X, was selected in multiple steps with VP-16. To prevent the development of typical multidrug resistance, an inhibitor of P-glycoprotein, the tiapamil analog, RO-11-2933, was added to the selections. The resultant clone FVP3 is 56-fold resistant to VP-16 and cross-resistant to doxorubicin (Adriamycin) (9-fold) and VM-26 (27-fold). These cells are also two- to fourfold resistant to m-AMSA, daunorubicin, and mitoxantrone. FVP3 is not resistant to the P-glycoprotein substrate vinblastine, does not express the MDR1 gene at detectable levels, and does not show reduced 3H-VP-16 accumulation. Unlike other cell lines that exhibit resistance to inhibitors of topoisomerase II, FVP3 has the same level of topoisomerase II expression and activity as FEM-X. Using live cells treated with VP-16, band depletion assays and KCl/SDS precipitation assays show that topoisomerase II from FVP3 is much less susceptible to drug-induced cleavable complex formation than is that from FEM-X. This difference in sensitivity to VP-16 is also detected using lysates from disrupted cells, but not with isolated nuclei devoid of cytoplasmic and membrane components. In addition, the topoisomerase II present in nuclear extracts from FVP3 is not resistant to the effects of VP-16 as measured by: (1) inhibition of strand passing activity during decatenation of kinetoplast DNA, (2) drug-induced linearization of plasmid DNA, and (3) immunodepletion by VP-16. These results suggest that some component of the cytoplasm or cellular membranes, or a factor depleted from nuclei during their isolation, is responsible for the resistance to VP-16 in FVP3.

Original languageEnglish
Pages (from-to)414-425
Number of pages12
JournalJournal of Cellular Physiology
Volume155
Issue number2
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Type II DNA Topoisomerase
Etoposide
Melanoma
Pharmaceutical Preparations
Topoisomerase II Inhibitors
P-Glycoprotein
Finite element method
Doxorubicin
Tiapamil Hydrochloride
Assays
Cells
Kinetoplast DNA
Amsacrine
Teniposide
Membranes
Cell Line
Mitoxantrone
Daunorubicin
Vinblastine
Multiple Drug Resistance

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cite this

Campain, J. A., Padmanabhan, R., Hwang, J., Gottesman, M. M., & Pastan, I. (1993). Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Journal of Cellular Physiology, 155(2), 414-425.

Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. / Campain, J. A.; Padmanabhan, R.; Hwang, J.; Gottesman, M. M.; Pastan, I.

In: Journal of Cellular Physiology, Vol. 155, No. 2, 1993, p. 414-425.

Research output: Contribution to journalArticle

Campain, JA, Padmanabhan, R, Hwang, J, Gottesman, MM & Pastan, I 1993, 'Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II', Journal of Cellular Physiology, vol. 155, no. 2, pp. 414-425.
Campain, J. A. ; Padmanabhan, R. ; Hwang, J. ; Gottesman, M. M. ; Pastan, I. / Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. In: Journal of Cellular Physiology. 1993 ; Vol. 155, No. 2. pp. 414-425.
@article{ab764466573048359ecf89223ee5ae8e,
title = "Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II",
abstract = "The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. To characterize resistance to this drug, the human melanoma cell line, FEM-X, was selected in multiple steps with VP-16. To prevent the development of typical multidrug resistance, an inhibitor of P-glycoprotein, the tiapamil analog, RO-11-2933, was added to the selections. The resultant clone FVP3 is 56-fold resistant to VP-16 and cross-resistant to doxorubicin (Adriamycin) (9-fold) and VM-26 (27-fold). These cells are also two- to fourfold resistant to m-AMSA, daunorubicin, and mitoxantrone. FVP3 is not resistant to the P-glycoprotein substrate vinblastine, does not express the MDR1 gene at detectable levels, and does not show reduced 3H-VP-16 accumulation. Unlike other cell lines that exhibit resistance to inhibitors of topoisomerase II, FVP3 has the same level of topoisomerase II expression and activity as FEM-X. Using live cells treated with VP-16, band depletion assays and KCl/SDS precipitation assays show that topoisomerase II from FVP3 is much less susceptible to drug-induced cleavable complex formation than is that from FEM-X. This difference in sensitivity to VP-16 is also detected using lysates from disrupted cells, but not with isolated nuclei devoid of cytoplasmic and membrane components. In addition, the topoisomerase II present in nuclear extracts from FVP3 is not resistant to the effects of VP-16 as measured by: (1) inhibition of strand passing activity during decatenation of kinetoplast DNA, (2) drug-induced linearization of plasmid DNA, and (3) immunodepletion by VP-16. These results suggest that some component of the cytoplasm or cellular membranes, or a factor depleted from nuclei during their isolation, is responsible for the resistance to VP-16 in FVP3.",
author = "Campain, {J. A.} and R. Padmanabhan and J. Hwang and Gottesman, {M. M.} and I. Pastan",
year = "1993",
language = "English",
volume = "155",
pages = "414--425",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II

AU - Campain, J. A.

AU - Padmanabhan, R.

AU - Hwang, J.

AU - Gottesman, M. M.

AU - Pastan, I.

PY - 1993

Y1 - 1993

N2 - The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. To characterize resistance to this drug, the human melanoma cell line, FEM-X, was selected in multiple steps with VP-16. To prevent the development of typical multidrug resistance, an inhibitor of P-glycoprotein, the tiapamil analog, RO-11-2933, was added to the selections. The resultant clone FVP3 is 56-fold resistant to VP-16 and cross-resistant to doxorubicin (Adriamycin) (9-fold) and VM-26 (27-fold). These cells are also two- to fourfold resistant to m-AMSA, daunorubicin, and mitoxantrone. FVP3 is not resistant to the P-glycoprotein substrate vinblastine, does not express the MDR1 gene at detectable levels, and does not show reduced 3H-VP-16 accumulation. Unlike other cell lines that exhibit resistance to inhibitors of topoisomerase II, FVP3 has the same level of topoisomerase II expression and activity as FEM-X. Using live cells treated with VP-16, band depletion assays and KCl/SDS precipitation assays show that topoisomerase II from FVP3 is much less susceptible to drug-induced cleavable complex formation than is that from FEM-X. This difference in sensitivity to VP-16 is also detected using lysates from disrupted cells, but not with isolated nuclei devoid of cytoplasmic and membrane components. In addition, the topoisomerase II present in nuclear extracts from FVP3 is not resistant to the effects of VP-16 as measured by: (1) inhibition of strand passing activity during decatenation of kinetoplast DNA, (2) drug-induced linearization of plasmid DNA, and (3) immunodepletion by VP-16. These results suggest that some component of the cytoplasm or cellular membranes, or a factor depleted from nuclei during their isolation, is responsible for the resistance to VP-16 in FVP3.

AB - The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. To characterize resistance to this drug, the human melanoma cell line, FEM-X, was selected in multiple steps with VP-16. To prevent the development of typical multidrug resistance, an inhibitor of P-glycoprotein, the tiapamil analog, RO-11-2933, was added to the selections. The resultant clone FVP3 is 56-fold resistant to VP-16 and cross-resistant to doxorubicin (Adriamycin) (9-fold) and VM-26 (27-fold). These cells are also two- to fourfold resistant to m-AMSA, daunorubicin, and mitoxantrone. FVP3 is not resistant to the P-glycoprotein substrate vinblastine, does not express the MDR1 gene at detectable levels, and does not show reduced 3H-VP-16 accumulation. Unlike other cell lines that exhibit resistance to inhibitors of topoisomerase II, FVP3 has the same level of topoisomerase II expression and activity as FEM-X. Using live cells treated with VP-16, band depletion assays and KCl/SDS precipitation assays show that topoisomerase II from FVP3 is much less susceptible to drug-induced cleavable complex formation than is that from FEM-X. This difference in sensitivity to VP-16 is also detected using lysates from disrupted cells, but not with isolated nuclei devoid of cytoplasmic and membrane components. In addition, the topoisomerase II present in nuclear extracts from FVP3 is not resistant to the effects of VP-16 as measured by: (1) inhibition of strand passing activity during decatenation of kinetoplast DNA, (2) drug-induced linearization of plasmid DNA, and (3) immunodepletion by VP-16. These results suggest that some component of the cytoplasm or cellular membranes, or a factor depleted from nuclei during their isolation, is responsible for the resistance to VP-16 in FVP3.

UR - http://www.scopus.com/inward/record.url?scp=0027252799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027252799&partnerID=8YFLogxK

M3 - Article

VL - 155

SP - 414

EP - 425

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 2

ER -